title: Bladder cancer in 2010: how far have we come?
abstract: Bladder cancer is the fourth most common cancer and ranks eighth as a cause of death from cancer among men in the United States. Although guidelines assist in treatment, the art of managing bladder cancer, such as the decision to use neoadjuvant chemotherapy and the timing of cystectomy, is still variable. Bladder cancer has a propensity to recur, and with recurrence, a significant number of cases progress, which makes the early detection of high-risk patients imperative. Advances in detection, surveillance, and treatment of bladder cancer are reviewed in this article.
authors.affiliation: Department of Urology, University of Pitsburgh School of Medicine, 3471 Fifth Avenue, Pittsburgh, PA 15213-3233, USA. jacobsbl@upmc.edu
authors.forename: Bruce L
authors.initials: BL
authors.lastname: Jacobs
authors.forename: Cheryl T
authors.initials: CT
authors.lastname: Lee
authors.forename: James E
authors.initials: JE
authors.lastname: Montie
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D014408:Biomarkers, Tumor; D002277:Carcinoma / Q000473:pathology; D015653:Cystectomy; D003558:Cystoscopy; D003952:Diagnostic Imaging; D005819:Genetic Markers; D006801:Humans; D009130:Muscle, Smooth / Q000473:pathology / Q000601:surgery; D009361:Neoplasm Invasiveness; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control; D009367:Neoplasm Staging; D012307:Risk Factors; D012371:Robotics; D001749:Urinary Bladder Neoplasms / Q000175:diagnosis* / Q000235:genetics / Q000628:therapy*; D014547:Urinary Diversion
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D005819:Genetic Markers